AXA1125

DRUG3 trials

Sponsors

Axcella Health, Inc

Conditions

NAFLDNon Alcoholic Steatohepatitis (NASH)Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection

Phase 2

Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis

Axcella Health, IncNon Alcoholic Steatohepatitis (NASH)

Start: 2021-05-07End: 2023-10-31Target: 273Updated: 2022-09-08

Efficacy, Safety, Tolerability of AXA1125 in Fatigue After COVID-19 Infection

CompletedNCT05152849

Axcella Health, IncPost-Acute Sequelae of SARS-CoV-2 (PASC) Infection

Start: 2021-12-15End: 2022-06-29Updated: 2022-10-20

Unknown Phase

Study of the Safety and Tolerability of AXA1125 and AXA1957 in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)

CompletedNCT04073368

Axcella Health, IncNAFLD

Start: 2018-12-03End: 2020-09-03Updated: 2021-07-06

Related Papers

Integrated longitudinal multiomics study identifies immune programs associated with acute COVID-19 severity and mortality

Journal of Clinical Investigation2024-04-3028 citations

Insights Into Long COVID Fatigue Biology: Potential Treatment Implications Using Multi-Targeted Action of AXA1125, a Novel Endogenous Metabolic Modulator Composition

Medical Research Archives2024-01-011 citations

Efficacy and tolerability of an endogenous metabolic modulator (AXA1125) in fatigue-predominant long COVID: a single-centre, double-blind, randomised controlled phase 2a pilot study.

2023-04-1426 citations

STIMULATE-ICP: A pragmatic, multi-centre, cluster randomised trial of an integrated care pathway with a nested, Phase III, open label, adaptive platform randomised drug trial in individuals with Long COVID: A structured protocol

PLoS ONE2023-02-1529 citations

752-P: LIVRQNac (AXA1125) Enhances Insulin Sensitivity in Primary Human Hepatocytes and in Subjects with NAFLD and T2D

Diabetes2021-06-01